Trial Profile
A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Melanoma vaccine gp100
- Indications Malignant melanoma
- Focus Therapeutic Use
- 11 Oct 2011 Actual end date May 2011 added as reported by ClinicalTrials.gov.
- 11 Oct 2011 Actual end date May 2011 added as reported by ClinicalTrials.gov.
- 11 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.